ASSOCIATION OF GSTO1 AND GSTO2 POLYMORPHISM WITH RISK OF END-STAGE RENAL DISEASE DEVELOPMENT AND PATIENT SURVIVAL

Slavica Cimbaljevic1, Sonja Suvakov2, Marija Matic2, Marija Pljesa-Ercegovac2, Tatjana Pekmezovic3, Tanja Radic2, Vesna Coric2, Tatjana Damjanovic4, Nada Dimkovic4, Rodoljub Markovic5, Ana Savic-Radojevic2, Tatjana Simic2

1 Serbian Chamber of Biochemists
2 Institute of Medical and Clinical Biochemistry, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
3 Institute of Epidemiology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
4 Clinical Department for Renal Diseases, Zvezdara University Medical Center, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
5 Department of Nephrology and Hemodialysis, University Teaching Hospital Zemun, Belgrade, Serbia

Summary

Background: Oxidative stress in patients with end-stage renal disease (ESRD) is associated with long-term cardiovascular complications. The cytosolic family of glutathione S-transferases (GSTs) is involved in the detoxication of various toxic compounds and antioxidant protection. GST omega class members, GSTO1 and GSTO2 possess, unlike other GSTs, dehydroascorbate reductase and deglutathionylation activities. The aim of this study was to clarify the role of genetic polymorphisms of GSTO1 (rs4925) and GSTO2 (rs156697) as risk determinants for ESRD development, as well as in the survival of these patients.

Methods: A total of 199 patients and 199 healthy subjects were included in the study and genotyped for both GSTO1 and GSTO2 polymorphism. Protein thiol and carbonyl groups as markers of protein oxidative damage were determined spectrophotometrically. Cox proportional hazard model and Kaplan-Meier analysis were performed to investigate the role of GSTO1 and GSTO2 genetic polymorphism on mortality of ESRD patients during the follow-up period (36 month).

Results: Individuals carrying the variant GSTO2 GG genotype were at 2.45-fold higher risk of ESRD development compared to the wild type GSTO2 AA genotype (OR=2.45; 95%CI=1.18–5.07; p=0.016). The results of GSTO1/GSTO2 haplotype analysis showed that individuals with the GSTO1/GSTO2 haplotype GT were at 1.5-fold higher risk of ESRD development compared to the wild type GSTO1/GSTO2 genotype (OR=1.5; 95%CI=1.1–2.0; p=0.016). The results of GSTO1/GSTO2 haplotype analysis showed that individuals with the GSTO1/GSTO2 haplotype GT were at 1.5-fold higher risk of ESRD development compared to the wild type GSTO1/GSTO2 genotype (OR=1.5; 95%CI=1.1–2.0; p=0.016).

Rezultati: Osobe sa varijantnim GSTO2 GG genotipom su bile pod 2,45 puta većim rizikom za razvoj TSB u odnosu na bolesnike sa referentnim GSTO2 AA genotipom (OR=2,45; 95%CI=1,18–5,07; p=0,016). Rezultati GSTO1/GSTO2 haplotip analize pokazali su da haplotip

| Address for correspondence: |
| Tatjana Simic |
| Pasterova 2, Institute of Medical and Clinical Biochemistry, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia |
| Phone number: +381113643250 |
| Fax number: +381113643270 |
| e-mail: tatjanasimic@med.bg.ac.rs |

List of abbreviations: GST – glutathione transferase, ESRD – end-stage renal disease, DHAR – dehydroascorbate reductase, SNP – single nucleotide polymorphism, HD – hemodialysis.
GSTO2 haplotype analysis showed that the haplotype combination of GSTO1 *(A)*/GSTO2 *(A)* (GSTO1 variant/GSTO2 wild type allele) was protective for ESRD (OR=0.23; 95% CI=0.12–0.44, p=0.001). Patients carrying at least one GSTO1 reference allele have shorter mean overall (Log rank=2.844, p=0.241) and cardiovascular survival probability (Log rank=6.211, p=0.122).

Conclusions: GSTO polymorphisms have been shown to act as significant markers in assessing the risk of ESRD development and patients’ survival.

Keywords: end-stage renal disease, genetic polymorphism, glutathione S-transferase, oxidative stress

Introduction

Oxidative stress is present in patients with end-stage renal disease (ESRD) (1). Moreover, there is a huge body of evidence implying that the prooxidant state is associated with long-term complications which include atherosclerosis and cardiovascular diseases (2–4), renal anemia (5), malnutrition (6), and bone disorders (7), and are the main cause of the increased morbidity and mortality of ESRD patients.

In the chronically hemodialyzed ESRD patients oxidative stress is primarily caused by accumulation of uremic toxins (8), phagocytes activation during the recurrent contact of blood with dialysis membranes, as well as dialyzer’s membrane bioincompatibility (9), and use of intravenous iron preparations to correct anemia (10). Furthermore, ESRD patients frequently have lower levels of water soluble antioxidant vitamins which is a consequence of dietary restriction of fresh fruits and vegetables to avoid hyperkalaemia (11, 12). During the hemodialysis (HD) session, there is also a waste of low molecular antioxidants, such as ascorbic acid, vitamin C (13). In addition, it has been shown that low plasma vitamin C level predicts fatal and major non-fatal adverse cardiovascular events among ESRD patients (14, 15). In addition to the association of oxidative stress with renal failure development, hemodialysis and uremia, interest in the role of genetic predisposition towards oxidative damage and ESRD patients’ prognosis has started to emerge recently. The family of glutathione S-transferases (GSTs) is a part of the cellular phase II detoxification program composed of multiple isoenzymes with functional polymorphisms in humans, that have the capacity to influence individual response to oxidative and electrophilic stresses. Their catalytic activity is expressed through GST dimer-mediated thioether conjugate formation with resultant detoxification of a variety of small molecule electrophils, including uremic toxins and reduction of accumulated hydroperoxides (16–18). The family of cytosolic GSTs includes the Alpha (GSTA), Mu (GSTM), Pi (GSTP), Theta (GSTT) and Omega (GSTO) class and all these genetic polymorphisms occur within GST family members, resulting in complete lack or lowering of enzyme activity (19). GSTM1 null, GSTT1 null or GSTP1 low activity genotype are associated with both increased risk of ESRD development and more pronounced oxidative stress in hemodialyzed patients (20).

It should be emphasized that in addition to the classic catalytic functions, specific GST isoenzymes, such as GSTO1 and GSTO2, catalyze reactions that impact antioxidant defense in ways unrelated to detoxification. These reactions include facilitation of the addition of glutathione to cysteine residues in certain proteins (forward reaction, S-glutathionylation) as a protective mechanism of sensitive protein thiol groups in conditions of oxidative stress and reverse reaction of deglutathionylation (21), aimed at regenerating thiol groups after oxidant attack, catalyzed by glutaredoxins, thioredoxin and protein disulfide isomerase, as well as GSTO1. Moreover, deglutathionylation activity of GSTO1 is influenced by a single nucleotide polymorphism (SNP) (rs4925, 419C to A) reported at nucleotide 419 causing an alanine to aspartate substitution in amino acid 140 (A140D) of exon 4 of GSTO1, resulting in lower deglutathionylation activity in carriers of GSTO1*A gene variant (21). Another reaction atypical for other GSTs but catalyzed by both GSTO1 and GSTO2 is dehydroascorbate reductase (DHAR) activity, a reaction important for ascorbic acid level preservation. GSTO2 is suggested to have the highest DHAR activity in the cells, which is up to 100 times higher than GSTO1 DHAR activity (22). An SNP of GSTO2 gene was found at nucleotide 424 causing an asparagine to aspartate substitution in amino acid 142 (N142D) of exon 4 (rs156697, 424 A to G) (23). Although the functional significance of GSTO1 and GSTO2 gene SNP is still under investigation, attempts were made to establish whether variant alleles confer higher risk of various types of malignancies (24, 25) and nonmalignant diseases (26–29).

In view of the important roles that both members of GST omega class play in redox homeostasis, it may be reasonable to assume that their polymorphic expression might be associated with ESRD development and prognosis. Therefore, in this study, we assessed whether GSTO1 and GSTO2 polymorphisms have a modifying effect in terms of ESRD development, as well as overall and cardiovascular mortality of hemodialyzed patients.
Materials and Methods

Study subjects

The case-control study included 199 stable patients (84 male and 115 female, mean age 59.9±12.2 years) hemodialyzed 3 times/week and recruited from two dialysis centers (Center for Renal Diseases, Zvezdara University Medical Center and Department of Nephrology and Hemodialysis, University Teaching Hospital Zemun). Inclusion criteria were that patients were older than 21 and at least 3 months on hemodialysis before entering the study. Patients with malignancy or infectious co-morbidity were excluded from the study. Patients were not prescribed vitamin C or E as antioxidant therapy. Control group included 199 age and gender matched individuals with nephrolithiasis and normal renal function. All the participants gave written informed consent and the ethical approval was obtained by the local Ethics Committee. The research was carried out in compliance with the Helsinki Declaration (as revised in 2000).

Both overall and cardiovascular mortality were prospectively registered during a follow-up period of 36 months. Zero time in this study is defined as the time when patients started regular HD treatment. Data regarding patients’ survival were obtained from hospital documents. For death to be classified as cardiovascular, a myocardial infarction and/or stroke should have occurred. A cardiologist diagnosed myocardial infarction based on clinical presentation, ECG and specific enzyme analysis. Stroke was diagnosed by a neurologist based on clinical presentation and CT scan.

GST genotyping

DNA was isolated from whole blood using the QIAGEN QIAmp kit (Qiagen, Inc., Chatsworth, CA). GSTO1 (rs 4925) and GSTO2 (rs156697) polymorphisms were determined by the PCR-RFLP method as previously described by Djukic et al. (25, 30).

Measurement of protein oxidative damage in plasma

In order to determine the degree of protein oxidative damage, the level of protein thiol groups (30) and carbonyl derivatives were measured (OxiSelect TM ELISA kits, Cell Biolabs).

Statistical analysis

For the statistical analysis, an SPSS program (version 17.0, Chicago, IL) was used. The continuous variables were presented by means ± standard deviations (SD). Logistic regression was used to test the associations between the genotypes and ESRD. All data were adjusted according to age and gender. The individual haplotype and its frequencies were estimated using the haplo.stats program. For survival analysis, the Kaplan-Meier method and long rank were used. We used three different models. The variables for Model 1 were adjusted to age and gender. Smoking status was added as an additional covariate for Model 2 while the Model 3 further obtained patients’ diabetes and cholesterol status.

Results

Baseline characteristics of 199 patients with end-stage renal disease were presented in Table I. Average HD vintage was 6.3±4.5 years. The main causes of death were cardiovascular diseases, infection and cachexia.

The associations between GSTO1 and GSTO2 genotypes and ESRD risk were presented in Table II. GSTO1 polymorphism was not significantly associated with risk of ESRD. However, individuals carrying variant GSTO2 GG genotype were at 2.45-fold higher risk of ESRD development compared to wild-type GSTO2 AA genotype carrying individuals (OR=2.45; 95%CI=1.18–5.07; p=0.016).

The results regarding haplotype GSTO1 and GSTO2 polymorphisms analysis were presented in Table III. GSTO1*C and GSTO2*A haplotype had the highest frequency among both patients (55.1%) and controls (45.5%). Furthermore, the results of haplotype analysis showed that the haplotype combination of one copy of variant GSTO1*A and one copy of wildtype GSTO2*A allele was protective for ESRD (OR=0.23; 95%CI=0.12–0.44; p=0.001).

| Variable                  | ESRD patients |
|---------------------------|---------------|
| Age (years)\(^a\)         | 59.9±12.2     |
| Gender, n (%)             |               |
| Female                    | 84 (42)       |
| Male                      | 115 (58)      |
| Time on hemodialysis (years) | 6.3±4.5      |
| Diabetes, n (%)           |               |
| Present                   | 25 (13)       |
| Absent                    | 174 (87)      |
| Smoking, n (%)            |               |
| Current + Former (ever)   | 55 (28)       |
| Never                     | 144 (72)      |
| BMI (kg/m\(^2\))          | 24.5          |
| Total cholesterol (mmol/L)| 4.7±1.1       |
| Triacylglycerol (mmol/L)  | 2.1±1.3       |

\(^a\)All results are presented as mean ± SD.

ESRD – end-stage renal disease; BMI – body mass index
Table II GST1 and GSTO2 genotypes in relation to risk of chronic renal failure.

| GST genotype | ESRD ptsb [n (%)] | Controlsc [n (%)] | OR (95% CI) | p value |
|--------------|-------------------|-------------------|--------------|---------|
| **GST1**     |                   |                   |              |         |
| CC           | 81 (41)           | 65 (33)           | 1.00a        |         |
| CA           | 94 (47)           | 117 (59)          | 0.69 (0.45–1.07) | 0.098   |
| AA           | 23 (12)           | 16 (8)            | 1.24 (0.60–2.58) | 0.561   |

Global association p value 0.110

| GSTO2        | ESRD ptsd [n (%)] | Controls [n (%)] | OR (95% CI) | p value |
|--------------|-------------------|------------------|--------------|---------|
| AA           | 66 (34)           | 82 (42)          | 1.00         |         |
| AG           | 97 (51)           | 100 (51)         | 1.19 (0.77–1.85) | 0.427   |
| GG           | 28 (15)           | 14 (7)           | 2.45 (1.18–5.07) | 0.016   |

Global association p value 0.046

OR, odds ratio; CI, confidence interval; a reference category; adjusted by age and gender; ESRD – end-stage renal disease; GST1 genotyping was successful in 198 patients; GST1 genotyping was successful in 198 controls; GST2 genotyping was successful in 191 patients; GST2 genotyping was successful in 196 controls.

Table III Association of haplotype frequencies in patients with ESRD and controls.

| Genotype | Haplotype frequencies (%) | ESRD pts | Controls | OR (95% CI) | p value |
|----------|---------------------------|----------|----------|-------------|---------|
| GST1     | GSTO2                     | ESRD     | Controls | OR (95% CI) | p value |
| C        | A                         | 55.1     | 45.5     | 1.00a       |         |
| A        | G                         | 30.6     | 15.9     | 1.47 (0.97–2.23) | 0.071   |
| C        | G                         | 9.6      | 16.7     | 0.62 (0.38–1.03) | 0.068   |
| A        | A                         | 4.7      | 21.9     | 0.23 (0.12–0.44) | 0.001   |

Global haplotype association p value 0.001

OR, odds ratio; CI, confidence interval
a Reference category
Adjusted by age and gender
ESRD – end-stage renal disease

Table IV represented the level of protein oxidative damage in ESRD patients regarding GST1 and GSTO2 genotypes. Plasma protein thiol groups’ concentrations were decreased in ESRD patients carriers of at least one GST1 or GSTO2 wild-type allele compared to GST1 or GSTO2 variant allele homozygotes, although statistically insignificantly (p=0.195; p=0.169). On the other hand, plasma protein carbonyl groups’ concentration in ESRD patients did not differ between ESRD patients with different GST1 or GSTO2 genotypes.

The Kaplan-Meier survival analysis demonstrated shorter mean overall (log rank=2.844, p=0.241) and cardiovascular survival probability (log rank=4.211, p=0.122) after the initiation of dialysis in patients carriers of at least one GST1 wild-type allele (Figure 1A and 2A) compared to GST1 AA homozygotes, although statistically insignificant. As presented in Figure 1B and 2B, there is no difference between GSTO2 gene variants and mean overall and cardiovascular survival probability.

Table IV Plasma thiol and carbonyl groups concentration in relation to GST1 and GSTO2 genotype in ESRD patients.

| GST genotype | GST1 | GSTO2 | SH groups (µmol/g) | Carbonyl groups (nmol/mg) |
|--------------|------|-------|--------------------|--------------------------|
|               | CC+CA | AA    | p                  |                           |
| SH groups (µmol/g) | 6.31 (3.27–10.91) | 6.94 (3.32–10.64) | 0.195 | 6.31 (3.76–10.90) | 7.36 (3.27–10.91) | 0.169 |
| Carbonyl groups (nmol/mg) | 2.25 (1.54–3.74) | 2.15 (1.54–2.92) | 0.441 | 2.25 (1.54–3.74) | 2.20 (1.82–2.92) | 0.784 |

Data are presented as medians with 95% confidence intervals
SH – thiol, GST – glutathione transferase, ESRD – end-stage renal disease
The results obtained by Cox regression analysis demonstrated that none of the GSTO1 gene variants were predictors for overall mortality in all three models tested (Table V). However, GSTO1 gene variants were predictors of a higher risk of cardiovascular mortality among ESRD patients in all tested models (global association p=0.052, p=0.04, p=0.036, respectively).

Regarding the prognostic role of GSTO2 polymorphism among ESRD patients (Table VI), the results obtained demonstrated that none of the GSTO2 gene variants were predictors for neither overall nor cardiovascular mortality in the models tested.

Further analysis of GSTO1 and GSTO2 haplotype gene variants with overall and cardiovascular mortality (Table VII) showed association only in case of overall mortality, still statistically insignificant (global haplotype association p=0.077).
**Table V** GSTO1 polymorphism as a predictor for overall and cardiovascular mortality among ESRD patients according to linear regression analysis.

| GSTO1 genotype | Model 1\(^a\) | Model 2\(^b\) | Model 3\(^c\) |
|----------------|----------------|----------------|----------------|
|                | HR (95% CI)    | p value        | HR (95% CI)    | p value        | HR (95% CI)    | p value        |
| A/A            | 1.00*          |                | 1.00           |                | 1.00           |                |
| C/C            | 1.28 (0.65–2.52) | 0.19           | 1.39 (0.70–2.76) | 0.17       | 1.24 (0.55–2.79) | 0.30       |
| A/A            | 0.43 (0.11–1.61) |                | 0.45 (0.12–1.73) |                | 0.43 (0.10–1.80) |                |

**Risk for overall mortality among carriers of various GSTO1 genotypes**

| GSTO1 genotype | Model 1\(^a\) | Model 2\(^b\) | Model 3\(^c\) |
|----------------|----------------|----------------|----------------|
|                | HR (95% CI)    | p value        | HR (95% CI)    | p value        | HR (95% CI)    | p value        |
| A/A            | 1.00           |                | 1.00           |                | 1.00           |                |
| C/C            | 1.60 (0.74–3.46) | 0.052         | 1.64 (0.76–3.55) | 0.04       | 1.86 (0.73–4.70) | 0.036      |
| A/A            | 0.23 (0.03–1.88) |                | 0.22 (0.03–1.78) |                | 0.20 (0.02–1.84) |                |

**Risk for cardiovascular mortality among carriers of various GSTO1 genotypes**

HR, hazard ratio; CI, confidence interval

*Reference category

ESRD – end-stage renal disease

\(^a\)Adjusted for age and gender; \(^b\)adjusted for the covariates in Model 1 plus an additional adjustment for smoking status; \(^c\)adjusted for the covariates in Model 2 plus an additional adjustment for diabetes and cholesterol, TAG and HDL levels.

---

**Table VI** GSTO2 polymorphism as a predictor for overall and cardiovascular mortality among ESRD patients according to linear regression analysis.

| GSTO2 genotype | Model 1\(^a\) | Model 2\(^b\) | Model 3\(^c\) |
|----------------|----------------|----------------|----------------|
|                | HR (95% CI)    | p value        | HR (95% CI)    | p value        | HR (95% CI)    | p value        |
| A/A            | 1.00*          |                | 1.00           |                | 1.00           |                |
| A/G            | 1.41 (0.68–2.93) | 0.43           | 1.59 (0.75–3.36) | 0.32       | 1.73 (0.69–4.31) | 0.26       |
| G/G            | 0.79 (0.27–2.35) |                | 0.86 (0.29–2.60) |                | 0.74 (0.21–2.66) |                |

**Risk for overall mortality among carriers of various GSTO2 genotypes**

| GSTO2 genotype | Model 1\(^a\) | Model 2\(^b\) | Model 3\(^c\) |
|----------------|----------------|----------------|----------------|
| A/A            | 1.00           |                | 1.00           |                | 1.00           |                |
| A/G            | 1.62 (0.69–3.78) | 0.36           | 1.59 (0.68–3.74) | 0.36       | 2.70 (0.87–8.39) | 0.092      |
| G/G            | 0.83 (0.23–3.00) |                | 0.79 (0.22–2.87) |                | 0.87 (0.18–4.23) |                |

**Risk for cardiovascular mortality among carriers of various GSTO2 genotypes**

HR, hazard ratio; CI, confidence interval

*Reference category

ESRD – end-stage renal disease

\(^a\)Adjusted for age and gender; \(^b\)adjusted for the covariates in Model 1 plus an additional adjustment for smoking status; \(^c\)adjusted for the covariates in Model 2 plus an additional adjustment for diabetes and cholesterol, TAG and HDL levels.
Discussion

In our study, frequencies of GSTO genotypes are within the range observed in the European population. Namely, the reported range for GSTO1 variant allele is 0.302–0.399 according to Polimanti et al. and Paiva L et al. (32, 33). We reported that the frequency of this allele was 0.37. For GSTO2 variant allele, the reported range of frequency in the European population is 0.31–0.341 (32, 34). The frequency obtained in our study was 0.33.

Our study demonstrated that individuals with variant GSTO2 GG genotype were at higher risk of ESRD development compared to the carriers of GSTO2 AA genotype. Additionally, the haplotype combination of one copy of variant GSTO1*A and one copy of wild-type GSTO2*A allele was protective for ESRD. The Kaplan-Meier survival analysis demonstrated shorter mean overall and cardiovascular survival probability, after the initiation of dialysis, in patients carriers of at least one GSTO1 wild-type allele compared to GSTO1 AA homozygotes, although statistically insignificant.

Polymorphisms of the omega class of GST in non-malignant diseases have been studied so far in several studies. The study of Allen et al. has shown that carriers of GSTO2 variant allele had increased risk for development of Alzheimer disease (26). The influence of GSTO2 polymorphism has also been investigated in the risk of hypothyroidism development and it has been reported that the carriers of variant GSTO2 genotype had almost five times higher risk for developing hypothyroidism (27). The study of Stamenkovic et al. (29) addressed the influence of GSTO1 polymorphism Ala140Asp and GSTO2 polymorphism Asn142Asp on the risk of age-related cataract. The results indicate that mutant GSTO2*Asp genotype is associated with increased risk of age-related cataract in smokers and ultraviolet-exposed subjects. However, these polymorphisms have not been widely studied in ESRD. Interestingly, there is only one study of GSTO2 genetic polymorphism in patients with ESRD done in Iran (35). They reported that GSTO2 genetic variant had no significant association with the ESRD risk. This result is in contrast to our findings, since we have reported that individuals with variant GSTO2 GG genotype were at higher risk of ESRD development compared to carriers of GSTO2 AA genotype. Since it has been speculated that rs156697 polymorphism of GSTO2 may influence its DHAR activity, our findings are biologically plausible due to the role of GSTO2 in regeneration of dehydroascorbate. Namely, chronically hemodialyzed patients show depletion of low molecular antioxidants, such as ascorbic acid (14). On the other hand, the reduction of dehydroascorbate to ascorbic acid is a vital cellular function. It is well established that various causes of ESRD, such as hypertension, diabetes and inflammation (e.g. glomerulonephritis), activate different molecular pathways which increase free radical production in the kidney. In subjects with both variant GSTO2 alleles, low enzyme activity probably causes lower DHAR activity and consequently low vitamin C level in the serum, as well as insufficient antioxidant protection. Polymorphic GSTO2 expression may result in inter-individual differences in antioxidant capacity in hemodialyzed patients. Unfortunately, we failed to show a correlation between GSTO2 polymorphism and oxidative phenotype determined as levels of protein oxidative stress byproducts.

Table VII  Haplotype association with risk for overall and cardiovascular mortality among ESRD patients.

| Haplotype | Haplotype frequencies (%) | OR (95% CI) | p value |
|-----------|---------------------------|-------------|---------|
| GSTO1     | GSTO2                     |             |         |
| C         | A                         | 53.7        | 58.5    |         |
| A         | G                         | 30.3        | 31.6    | 0.97 (0.52–1.80) | 0.92 |
| C         | G                         | 9.9         | 8.8     | 0.79 (0.32–1.92) | 0.60 |
| A         | A                         | 6.1         | 1.1     | 0.00 (0.00–NA)   | 1    |

Global haplotype association p value 0.077

| Haplotype | Haplotype frequencies (%) | OR (95% CI) | p value |
|-----------|---------------------------|-------------|---------|
| GSTO1     | GSTO2                     |             |         |
| C         | A                         | 54.2        | 57.1    | 1       |
| A         | G                         | 30.2        | 31.3    | 1.01 (0.50–2.02) | 0.99 |
| C         | G                         | 10.0        | 10.0    | 1.00 (0.36–2.77) | 1    |
| A         | A                         | 5.6         | 1.6     | 0.00 (0.00–NA)   | 1    |

Global haplotype association p value 0.260

OR, odds ratio; CI, confidence interval; *reference category; adjusted for age and gender; ESRD – end-stage renal disease
GSTO2 polymorphism seems not to be involved in the course of prognosis of ESRD patients. However, GSTO1 polymorphism influences overall and cardiovascular survival probability of these patients, which is not in accordance with the findings of Peddareddy et al. who showed that GSTO1 gene C419A polymorphism was not involved in cerebral response to ischemia (36), while Kölsch et al. (37) showed that the carriers of at least one variant GSTO1*A allele had an increased risk of stroke. Although it has been pointed out that this SNP causes reduced enzyme activity and therefore tissue susceptibility to oxidative stress, recent findings revealing the functional role of this polymorphism in the glutathionylation/deglutathionylation cycle might provide additional explanations for the accelerated death in patients with GSTO1*C wild-type allele (21). Thus, Menon and Board (21) suggested that GSTO1 genetic variants may influence regulation of glutathionylation, indicating GSTO1*C wild-type allele as a protein with higher deglutathionylation activity than the variant one. With an idea that glutathionylation impacts both protein structure and function, the differences in polymorphic expression of GSTO1 could provide a plausible mechanism to explain the link between this genetic polymorphism and different diseases (24–29). In our study, the haplotype combination of one copy of wild-type GSTO1*C and one copy of variant GSTO2*G allele was deleterious for ESRD risk, while the carriers of wild-type GSTO1 CC had lower survival. It should be emphasized that in ESRD progression, altered redox regulation shifts biomolecules towards a more oxidized state (20, 38). Thiol groups are among the most sensitive targets of prooxidant compounds in ESRD, which reflect the level of oxidative stress in these patients (38, 39). Impaired homeostasis of blood thiols in ESRD includes a disturbance of redox pairs, such as GSH/GSSG and cysteine/cystine, in plasma and blood cells (40). Protein thiols (P-SH) are also modified, while albumins act as sacrificial antioxidants, as confirmed in this and other investigations which found that titrable P-SH are decreased in plasma specimens (20, 41). Among the posttranslational modifications of P-SH of relevance for these effects in ESRD patients, there are alkylation reactions produced by a series of electrophilic carboxyls and oxidation to sulfenic acid by the action of reactive species (41). Further oxidation of sulfenic acid to sulfuric and sulfonic acid leads to protein degradation. Such an unfavorable sequence of reactions is prevented by the so-called S-glutationylation cycle, in which glutathione molecules are added to protein cysteins forming mixed disulfides P-S-S-G (42). This so-called forward glutathionylation reaction might occur spontaneously, but is also catalyzed by another GST enzyme family member, GSTP1 (42). Indeed, our previous results showed decreased thiol group concentration in ESRD patients in homozygous carriers of GSTP1 Val/Val compared to carriers of at least one GSTP1 Ile wildtype allele (20). Although changes in protein S-glutationylation have still not been documented in ESRD patients, a recent work by Galli et al. (39) showed increased plasma protein thiolation. It might be speculated that the presence of a GSTO1*C allelic variant might also be in favor of protein deglutationionylation, and higher susceptibility to oxidation by oxidant species, resulting in more protein modifications and enhanced vascular oxidant stress. Thus, in our study, plasma protein thiol groups were decreased in ESRD patients who were carriers of at least one GSTO1*C wild-type allele. This probably reflects the overall process of oxidative damage, and the role of albumins as sacrificial targets. In order to establish the potential role of GSTO1 polymorphism in the glutathionylation/deglutathionylation cycle, a wide range of cellular proteins should be targeted.

Limitations of this study include a hospital-based control group, a relatively small sample size, its cross-sectional design and short follow-up period. Use of population controls may have been more appropriate in this study. The case-control design was used to assess the associations between glutathione transferases omega genotypes and ESRD development and, therefore, selection bias might impact the results.

In conclusion, this study offers some essential information that could be the base for future longitudinal research. Additionally, with these combined methodological approaches, we also confirmed the value of the GSTO polymorphisms as significant markers in assessing the risk of ESRD development and patients’ survival.

**Conflict of interest statement**

The authors stated that they have no conflicts of interest regarding the publication of this article.
References

1. Puchades MJ, Saez G, Munoz MC, Gonzalez M, Torregrosa I, Juan I, et al. Study of oxidative stress in patients with advanced renal disease and undergoing either hemodialysis or peritoneal dialysis. Clin Nephrol 2015; 80: 177–86.

2. Honda H, Ueda M, Kojima S, Mashiba S, Michihata T, Takahashi K, Shishido K, Akizawa T. Oxidized high-density lipoprotein as a risk factor for cardiovascular events in prevalent hemodialysis patients. Atherosclerosis 2012; 220: 493–501.

3. Bossola M, Vulpio C, Colacicco L, Scribano D, Zuppi C, Tazza L. Reactive oxygen metabolites (ROMs) are associated with cardiovascular disease in chronic hemodialysis patients. Clin Chem Lab Med 2012; 50: 1447–53.

4. Cvetković T, Veličković-Radovanić R, Stojanović D, Stefanović N, Ignjatović A, Stojanović I, Sladojević N, Pavlović D. Oxidative and nitrosative stress in stable renal transplant recipients with respect to the immunosuppression protocol – differences or similarities? J Med Biochem 2015; 34: 295–303.

5. Rusu A, Rusu F, Zaluchti D, Muresan A, Gherman Caprioara M, Kacso I. The influence of vitamin E supplementation on erythropoietin responsiveness in chronic hemodialysis patients with low levels of erythrocyte superoxide dismutase. Int Urol Nephrol 2013; 45: 495–501.

6. Kotur-Stevelurjev J, Simić-Ogrizovic S, Dopsaj V, Stefanović A, Vujovic A, Ivanic-Corlomanovic T, et al. A hazardous link between malnutrition, inflammation and oxidative stress in renal patients. Clin Biochem 2012; 45(15): 1202–5.

7. Tanaka H, Komaba H, Koizumi M, Kakuta T, Fukagawa M. Role of uremic toxins and oxidative stress in the development of chronic kidney disease – mineral and bone disorder. J Ren Nutr 2012; 22: 98–101.

8. Jourde-Chiche N, Dou L, Cerini C, Dignat-George F, Brunet P. Vascular incompetence in dialysis patients—protein-bound uremic toxins and endothelial dysfuncion. Sem Dial 2011; 24: 327–37.

9. Dahe GJ, Teotia RS, Kadam SS, Bellare JR. The biocompatibility and separation performance of antioxidative polysulfone/vitamin E TPGS composite hollow fiber membranes. Biomaterials 2011; 32: 352–65.

10. Vaziri ND. Understanding iron: promoting its safe use in dialysis patients with low glomerular filtration rate or on dialysis: a review. Semin Dial 2013; 26: 546–7.

11. Takahashi N, Morimoto S, Oikigaki M, Seo M, Someya K, Morita T, et al. Decreased plasma level of vitamin C in chronic kidney disease: comparison between diabetic and nondiabetic patients. Nephrol Dial Transplant 2011; 26: 1252–7.

12. Clase CM, Ki V, Holden RM. Water-soluble vitamins in people with low glomerular filtration rate or on dialysis: a review. Semin Dial 2013; 26: 546–7.

13. Shi XF, Ding F, Zhu QY, Xue J, Lu FM, Gu Y, Lin ST. Use of ascorbate-rich dialysate to attenuate oxidative stress in maintenance hemodialysis patients. Ren Fail 2005; 27: 213–9.

14. Deicher R, Hörl WH. Vitamin C in chronic kidney disease and hemodialysis patients. Kidney Blood Press Res 2003; 26: 100–6.

15. Deicher R, Ziai F, Bieglmayer C, Schilling M, Hörl WH. Low total vitamin C plasma level is a risk factor for cardiovascular morbidity and mortality in hemodialysis patients. J Am Soc Nephrol 2005; 16: 1811–8.

16. Carmagnol F, Sinet PM, Rapin J, et al. Glutathione-S-transferase of human red blood cells; assay, values in normal subjects and in two pathological circumstances: hyperbilirubinemia and impaired renal function. Clin Chim Acta 1981; 117: 209–17.

17. Mimic-Oka J, Simic T, Djukanovic L, Stefanovski J, Ramic Z. Glutathione and its associated enzymes in peripheral blood cells in different stages of renal insufficiency. Amino Acids 1992; 2: 215–24.

18. Habig WH, Pabst MJ, Jakoby WB. Glutathione S-transferase – the first enzymatic step in mercapturic acid formation. J Biol Chem 1974; 249: 7130–9.

19. Hayes JD, Strange RC. Glutathione S-transferase polymorphisms and their biological consequences. Pharmacology 2000; 61: 154–66.

20. Suvakov S, Damjanovic T, Stefanovic A, Pekmezovic T, Savic-Radojevic A, Pljesa-Ercegovac M, et al. Glutathione S-transferase A1, M1, P1 and T1 null or low-activity genotypes are associated with enhanced oxidative damage among haemodialysis patients. Nephrol Dial Transplant 2013; 28: 202–12.

21. Menon D, Board PG. A role for Glutathione transferase Omega 1 (GSTO1-1) in the glutathionylation cycle. J Biol Chem 2013; 288: 25769–79.

22. Zhou H, Brock J, Liu D, Board PG, Oakley AJ. Structural insights into the dehydroascorbate reductase activity of human omega-class glutathione transferases. J Mol Biol 2012; 420: 190–203.

23. Board PG. The omega-class glutathione Transferase: structure, function, and genetics. Drug Metab Rev 2011; 43: 226–35.

24. Sanguansin S, Petmitr S, O-Charoenrat P, Pongsta porn Rep 2013; 40(2): 1967–71.

25. Fuciarelli M. GSTO2*N142D gene polymorphism associated with risk of transitional cell carcinoma of urinary bladder. Int Urol Nephrol 2015; 47: 625–30.

26. Allen M, Zou F, Chai HS, Younkin CS, Miles R, Nair AA. Glutathione S-transferase omega genes in Alzheimer and Parkinson disease risk, age-at-diagnosis and brain gene expression: an association study with mechanistic implications. Mol Neurodegener 2012; 7: 13.

27. Placentini S, Monaci PM, Polimanti R, Manfelliottod D, Fucirelli M. GSTO2*N142D gene polymorphism associated with hypothyroidism in Italian patients. Mol Biol Rep 2013; 40(2): 1967–71.
28. Piacentini S, Polimanti R, Iorio A, Cortesi M, Papa F, Rongioletti M, et al. GSTA1*-69C/T and GSTO2* N142D as asthma- and allergy-related risk factors in Italian adult patients. Clin Exp Pharmacol Physiol 2014; 41(3): 180–4.

29. Stamenkovic M, Radic T, Stefanovic I, Coric V, Sencanic I, Pljesa-Ercegovac M, et al. Glutathione S-transferase omega-2 polymorphism Asn142Asp modifies the risk of age-related cataract in smokers and subjects exposed to ultraviolet irradiation. Clin Experiment Ophthalmol 2014; 42: 277–83.

30. Novaković I, Maksimović N, Pavlović A, Žarković M, Rovčanin B, Mirković D, Pekmezović T, Cvetković D. Introduction to molecular genetic diagnostics. J Med Biochem 2014; 33: 3–7.

31. Jocelyn PC. Spectrophotometric assay of thiols. Methods Enzymol 1987; 143: 44–67.

32. Polimanti R, Piacentini S, Porreca F, Fuciarelli M. Glutathione S-transferase Omega class (GSTO) polymorphisms in a sample from Rome (Central Italy). Human Biological Survey 2010; 37: 585–92.

33. Paiva L, Marcos R, Creus A, Coggan M, Oakley AJ, Board PG. Polymorphism of glutathione transferase Omega 1 in a population exposed to a high environmental arsenic burden. Pharmacogenet Genomics 2008; 18: 1–10.

34. Whitbread AK, Tetlow N, Eyre HJ, Sutherland GR, Board PG. Characterization of the human Omega class glutathione transferase genes and associated polymorphisms. Pharmacogenetics 2003; 13: 131–44.

35. Nekooie-Marnany N, Saadat I, Karimi MH, Roozbeh J, Saadat M. Influence of GSTO2 (N142D) genetic polymorphism on acute renal rejection. Mol Biol Rep 2013; 40: 4857–60.

36. Peddareddyari LR, Dutra AV, Levenstien MA, Sen S, Grewal RP. An analysis of methylenetetrahydrofolate reductase and glutathione S-transferase omega-1 genes as modifiers of the cerebral response to ischemia. BMC Neurol 2009; 9: 37.

37. Kölsch H, Linnebank M, Lütjohann D, Jessen F, Wüllner U, Harbrecht U, et al. Polymorphisms in glutathione S-transferase omega-1 and AD, vascular dementia, and stroke. Neurology 2004; 63: 2255–60.

38. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002; 62: 1524–38.

39. Colombo G, Reggiani F, Podestà MA, Garavaglia ML, Portinaro NM, Milzani A, et al. Plasma protein thiolation index (PTI) as a biomarker of thiol-specific oxidative stress in haemodialyzed patients. Free Radic Biol Med 2015; 89: 443–51.

40. Galli F, Piroddi M, Bartolini D, Ciffolilli S, Buoncristiani E, Ricci G, et al. Blood thiol status and erythrocyte glutathione S-transferase in chronic kidney disease patients on treatment with frequent (daily) hemodialysis. Free Radic Res 2014; 48: 273–81.

41. Himmelfarb J, Monnagle E. Albumin is the major plasma protein target of oxidant stress in uremia. Kidney Int 2001; 60: 358–63.

42. Tew KD, Townsend DM. Glutathione-S-transferases as determinants of cell survival and death. Antioxid Redox Signal 2012; 17: 1728–37.

Received: January 6, 2016
Accepted: February 12, 2016